Please note, this OEL/ADE monograph also applies to barbital sodium (CAS RN 144-02-5). he first of the barbiturates to come onto the market was diethyl-barbituric acid, also known as barbital. Synthesized in 1881 by treating the argentic salt of barbituric acid with ethyl iodide, it was introduced clinically as a hypnotic by the German companies E Merck (Darmstadt) and F Bayer and Co (Elberfeld) in 1904. Barbital and its sodium salt, barbital sodium, are long-acting barbiturates that depress most metabolic processes at high doses. They were used as hypnotics and sedatives and may induce dependence. Barbital is also used in veterinary practice for central nervous system (CNS) depression. Barbital is a schedule IV-controlled drug.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for Barbital, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.